Citadel Advisors’s VYNE Therapeutics VYNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.72M | Sell |
1,040,070
-60,259
| -5% | -$99.4K | ﹤0.01% | 2819 |
|
|
2025
Q1 | $1.74M | Sell |
1,100,329
-130,128
| -11% | -$206K | ﹤0.01% | 2727 |
|
|
2024
Q4 | $4.12M | Buy |
1,230,457
+43,044
| +4% | +$144K | ﹤0.01% | 1956 |
|
|
2024
Q3 | $2.23M | Sell |
1,187,413
-23,653
| -2% | -$44.5K | ﹤0.01% | 2406 |
|
|
2024
Q2 | $2.39M | Buy |
1,211,066
+29,978
| +3% | +$59.1K | ﹤0.01% | 2280 |
|
|
2024
Q1 | $3.63M | Hold |
1,181,088
| – | – | ﹤0.01% | 2010 |
|
|
2023
Q4 | $2.75M | Buy |
+1,181,088
| New | +$2.75M | ﹤0.01% | 2141 |
|
|
2023
Q1 | – | Sell |
-2,997
| Closed | -$8.09K | – | 6630 |
|
|
2022
Q4 | $8.09K | Sell |
2,997
-1,815
| -38% | -$4.9K | ﹤0.01% | 5712 |
|
|
2022
Q3 | $19K | Buy |
+4,812
| New | +$19K | ﹤0.01% | 5547 |
|
|
2022
Q2 | – | Sell |
-2,477
| Closed | -$29K | – | 6984 |
|
|
2022
Q1 | $29K | Buy |
2,477
+674
| +37% | +$7.89K | ﹤0.01% | 6065 |
|
|
2021
Q4 | $33K | Sell |
1,803
-1,470
| -45% | -$26.9K | ﹤0.01% | 6250 |
|
|
2021
Q3 | $81K | Buy |
3,273
+1,447
| +79% | +$35.8K | ﹤0.01% | 5967 |
|
|
2021
Q2 | $116K | Buy |
+1,826
| New | +$116K | ﹤0.01% | 5893 |
|
|
2021
Q1 | – | Hold |
0
| – | – | – | 6876 |
|
|
2020
Q3 | – | Sell |
-7,020
| Closed | -$875K | – | 5329 |
|
|
2020
Q2 | $875K | Buy |
7,020
+6,800
| +3,091% | +$848K | ﹤0.01% | 2970 |
|
|
2020
Q1 | $42K | Buy |
+220
| New | +$42K | ﹤0.01% | 4569 |
|
|
2019
Q1 | – | Sell |
-193
| Closed | -$57K | – | 5080 |
|
|
2018
Q4 | $57K | Buy |
+193
| New | +$57K | ﹤0.01% | 4092 |
|
|
2018
Q3 | – | Sell |
-223
| Closed | -$130K | – | 4760 |
|
|
2018
Q2 | $130K | Buy |
223
+25
| +13% | +$14.6K | ﹤0.01% | 3782 |
|
|
2018
Q1 | $535K | Buy |
+198
| New | +$535K | ﹤0.01% | 2868 |
|